Header Logo

Connection

Yuki Kageyama to Molecular Targeted Therapy

Back to Details
This is a "connection" page, showing publications Yuki Kageyama has written about Molecular Targeted Therapy.
Yuki Kageyama
Connection Strength
0.037
Molecular Targeted Therapy
  1. Early C-reactive protein kinetics predict survival of patients with advanced urothelial cancer treated with pembrolizumab. Cancer Immunol Immunother. 2021 Mar; 70(3):657-665.
    View in: PubMed
    Score: 0.037
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.